Targets › BMPR2
1 program from 1 company in 1 trial: 1 Phase 1; Cardiovascular; next expected readout Nov 2027.
On ligand binding, forms a receptor complex consisting of two type II and two type I transmembrane serine/threonine kinases. Type II receptors phosphorylate and activate type I receptors which autophosphorylate, then bind and activate SMAD transcriptional regulators. (UniProt, Q13873)
Open in Phaseline: the race on BMPR2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Diagonal Therapeutics | DIAG723 Bispecific agonist monoclonal antibody targeting ALK-1 and BMPRII | ALK1, BMPR2 | Phase 1 | Hereditary Hemorrhagic Telangiectasia | Nov 2027 |
Hereditary Hemorrhagic Telangiectasia (1)
protein or peptide (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.